Inhibrx Biosciences, INC

Inhibrx Biosciences has amended its loan agreement with Oxford Finance, increasing its credit facility to $500 million to support its clinical pipeline.

Inhibrx Biosciences announced the FDA has accepted its Biologics License Application for ozekibart (INBRX-109) for the treatment of conventional chondrosarcoma, with a PDUFA goal date of April 14, 2027.

Inhibrx Biosciences, Inc. held its 2026 Annual Meeting of Stockholders, where directors were elected and the appointment of its independent registered public accounting firm was ratified.

Inhibrx Biosciences announced its first quarter 2026 financial results, highlighting progress in its clinical pipeline and a strengthened cash position.

Inhibrx Biosciences announced positive interim Phase 2 data for INBRX-106 in first-line head and neck cancer, showing a significant increase in objective response rates when combined with pembrolizumab.

Inhibrx Biosciences, Inc. announced its financial results for the fiscal year 2025, highlighting a significant reduction in operating expenses and progress in its clinical programs for ozekibart and INBRX-106.

Inhibrx Biosciences reports Q1 2026 results, highlighting clinical trial advancements for ozekibart and INBRX-106, alongside a strengthened balance sheet through debt financing.

Inhibrx Biosciences announced positive Phase 2 results for ozekibart in chondrosarcoma, planning a Q2 2026 BLA submission, alongside promising interim data for other pipeline assets, despite reporting a net loss for the nine months ended September 30, 2025.

Inhibrx Biosciences reports significantly reduced operating expenses and a new debt facility in Q2 2025, as it awaits crucial clinical trial data for its lead therapeutic candidates later this year.

Inhibrx Biosciences announces its Q1 2025 financial results, showcasing a decrease in operating expenses and providing updates on its clinical development programs.

Inhibrx Biosciences reports its Q3 2024 results, highlighting a significant gain from a merger and providing updates on its clinical pipeline following a strategic separation.

Inhibrx Biosciences completed its spin-off and merger, reporting a significant gain from the transaction while continuing to advance its clinical pipeline.

Inhibrx Biosciences highlights clinical advancements in its oncology pipeline and details its financial position and strategies in its 2024 annual report.

Director Kristiina Vuori was granted 15,000 stock options in Inhibrx Biosciences, Inc. exercisable in 2027.

Director Jon Faiz Kayyem was granted 15,000 stock options in Inhibrx Biosciences, Inc. with an exercise price of $95.22.

Director Douglas Forsyth was granted 15,000 stock options in Inhibrx Biosciences, Inc. exercisable in 2027.

Director Kimberly Manhard was granted 15,000 stock options in Inhibrx Biosciences, Inc. exercisable in 2027.

Inhibrx Biosciences President David Matly was granted 50,000 stock options as part of a standard equity compensation package.

Viking Global Investors LP and affiliated entities reported the sale of 359,000 shares of Inhibrx Biosciences, Inc. common stock for $32.25 per share.

Inhibrx Biosciences, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 3, 2026, to elect directors and ratify the appointment of its independent auditor.

Inhibrx Biosciences, Inc. has filed a definitive proxy statement with the SEC.

Inhibrx Biosciences announces its 2025 Annual Meeting of Stockholders to be held virtually on May 28, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Inhibrx Biosciences registers for the resale of up to 2.4 million shares of its common stock following the completion of the INBRX-101 sale to Sanofi.

An amended Schedule 13D filing reveals Inhibrx Biosciences insider Jon Faiz Kayyem's increased beneficial ownership to 7.9% through personal funds and family trust transactions, while his family trust's direct ownership dropped below 5%.

Mark Lappe, a key insider at Inhibrx Biosciences, Inc., has increased his beneficial ownership in the company to 6.4% through a series of open-market purchases totaling 164,000 shares between August and September 2024.

Bank of America Corporation has reported beneficial ownership of 5.9% of Inhibrx Biosciences, Inc. common stock as of June 30, 2026.

Viking Global Investors filed an amended Schedule 13G to reflect the retirement of David C. Ott from its reporting group.

Perceptive Advisors, Joseph Edelman, and Perceptive Life Sciences Master Fund have filed a Schedule 13G reporting a 9.99% beneficial ownership stake in Inhibrx Biosciences, Inc.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have disclosed beneficial ownership of 7.9% of Inhibrx Biosciences, Inc.'s common stock.

BlackRock, Inc. has filed a Schedule 13G, reporting a 5.3% beneficial ownership stake in INHIBRX BIOSCIENCES, INC. as of December 31, 2025.

BlackRock, Inc. has reported a reduced beneficial ownership in Inhibrx Biosciences, Inc. to 4.7% of common stock.